Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
596 of 1583



Newsletter Sign Up

Daily Readings

Reading 1, Ephesians 2:1-10
And you were dead, through the crimes and the sins which used ... Read More

Psalm, Psalms 100:2, 3, 4, 5
serve Yahweh with gladness, come into his presence with songs ... Read More

Gospel, Luke 12:13-21
A man in the crowd said to him, 'Master, tell my brother to ... Read More

Saint of the Day

October 20 Saint of the Day

St. Paul of the Cross
October 20: St. Paul of the Cross was born at Ovada in the Republic of ... Read More